Jazz Pharmaceuticals plc – Ordinary Shares(NASDAQ:JAZZ) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 9, 2016. Company reported revenue of $381.16M. Analysts estimated a revenue of $375.99M. Earnings per share were $2.63. Analysts had estimated an EPS of $2.80.
In a different note, BMO Capital said it Initiates Coverage on Jazz Pharmaceuticals plc – Ordinary Shares, according to a research note issued on Jun 29, 2016. The shares have been rated ‘Outperform’ by the firm. Goldman Sachs said it Initiates Coverage on Jazz Pharmaceuticals plc – Ordinary Shares, according to a research note issued on Jun 6, 2016. The shares have been rated ‘Buy’ by the firm. On Jun 2, 2016, SunTrust Robinson Humphrey said it Maintains its rating on Jazz Pharmaceuticals plc – Ordinary Shares. In the research note, the firm Raises the price-target to $200.00 per share. The shares have been rated ‘Buy’ by the firm.
Jazz Pharmaceuticals plc – Ordinary Shares (JAZZ) shares turned negative on Wednesdays trading session with the shares closing down -0.22 points or -0.16% at a volume of 6,23,775. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $137.355. The peak price level was also seen at $137.355 while the days lowest was $135.02. Finally the shares closed at $136.31. The 52-week high of the shares is $188.24 while the 52-week low is $108.5. According to the latest information available, the market cap of the company is $8,251 M.
Several Insider Transactions has been reported to the SEC. On Jul 18, 2016, Michael Patrick Miller (SVP, US Commercial) sold 100 shares at $142.43 per share price.Also, On Jul 13, 2016, Karen L. Smith (Global Head of R&D and CMO) purchased 580 shares at $143.63 per share price.On May 26, 2016, Seamus Mulligan (director) sold 27,968 shares at $150.13 per share price, according to the Form-4 filing with the securities and exchange commission.